Helus Pharma Q2 Loss Widens On Higher Costs; Phase 3 Depression Data Due In Q4 2026

Helus Pharma (HELP) reported a wider Q2 loss of $103.09M, or $1.41 per share, due to higher costs. Operating expenses rose to $104.52M, with share-based compensation at $64.96M. The company has $171.07M in cash. HLP003 Phase 3 results are due in Q4 2026. Shares fell 13.53% on Monday.

Original reporting
Published Nov 17, 2026, 10:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Helus Pharma Q2 Loss Widens On Higher Costs; Phase 3 Depression Data Due In Q4 2026 — source image
Decision brief

The 30-second read

$HELPBearishMed
01

Why it matters

The update combines a materially wider quarterly loss with explicit cost drivers (notably share-based compensation) and milestone timing (Phase 3 topline expected in Q4 2026, Phase 2 monotherapy trial starting Q1 2027). This mix typically shifts traders toward cash-burn and dilution-risk modeling while waiting for the next clinical readout.

02

Market read

Traders get a fresh quarterly cost and loss datapoint plus concrete clinical timeline markers that affect near-term valuation and risk pricing.

03

What to watch

Cash balance is $171.07M as of Sept. 30, which could moderate dilution fears if burn stabilizes; also, enrollment completion in PARADIGM may reduce execution risk into Q4 2026.

Relevance 7/10Novelty 7/10Timing: pre-market today, after Monday’s close and earnings-style update

Background

Helus is a clinical-stage serotonergic agonist developer focused on depression (HLP003) and anxiety (HLP004), with Phase 3 PARADIGM enrollment completed and additional pivotal trials ongoing.

Company-level read

Ticker impact

$HELPBearishHigh confidence
Context

Helus reported a wider FY27 Q2 loss to $103.09M as share-based compensation and clinical spending rose, alongside Phase 3 timing updates.

Expected impact

Likely downside pressure as investors weigh cost acceleration and delayed clinical milestones against the cash runway.

Evidence & confidence

The article discloses a large jump in operating expenses driven by share-based compensation and clinical spending, plus Phase 3 topline timing and upcoming trial starts that extend the development timeline.

Market effects

Reinforces the biotech tape narrative that clinical-stage companies with rising opex and SBC face valuation pressure until clearer Phase 3 catalysts arrive.

Limited, company-specific move for US small-cap biotech.

Low, no cross-market policy or sector-wide regulatory trigger described.

Counterpoint

The cost increase is framed as continued advancement of HLP003 Phase 3 trials, so the market may be over-penalizing near-term burn ahead of topline.

Key entities

  • Helus Pharma Inc.

    Reported wider Q2 FY27 loss, higher operating expenses, and provided pipeline and trial timing updates.

  • HLP003 (PARADIGM)

    Phase 3 program with enrollment completed; topline expected in Q4 2026, with additional pivotal trials ongoing.

  • HLP004

    Generalized anxiety disorder program planning Phase 2 monotherapy trial in Q1 2027.

  • Michael Halstead

    Appointed CEO to lead through late-stage development and commercialization.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

MedAI 8/10

Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.